VeloGene Biotechnology Congratulates Partner AccurEdit Therapeutics on Receiving US FDA IND Clearance for In Vivo Gene Editing Therapy ART001

AccurEdit Therapeutics (Suzhou) Co., Ltd. (“AccurEdit”) announced that its self-developed product ART001 targeting transthyretin amyloidosis (ATTR) has recently received IND clearance from the U.S. FDA, making it the first non-viral vector-based in vivo gene editing drug from China to obtain…


